SARS-CoV-2 testing in the community: Testing positive samples with the TaqMan SARS-CoV-2 Mutation Panel to find variants in real-time
SARS-CoV-2 testing in the community: Testing positive samples with the TaqMan SARS-CoV-2 Mutation Panel to find variants in real-time
复制标题
社区中的 SARS-CoV-2 检测：使用 TaqMan SARS-CoV-2 Mutation Panel 检测阳性样本，实时发现变异
DOI：
10.1101/2021.11.17.21266297
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Ashford F
中科院分区：
文献类型：
--
作者：
Ashford F
基因组测序是鉴定SARS-CoV-2变异谱系的有力工具;然而，当用于鉴定特定的关键突变时，由于序列缺失，可能存在限制。最近，赛默飞世尔科技开发了基因分型检测技术，以帮助弥合检测能力和测序能力之间的差距，从而根据特定变体生成实时基因分型结果。在2021年4月至5月的6周内，我们开始评估ThermoFisher TaqMan突变面板基因分型检测，最初针对三个关注的突变，然后针对SARS-CoV-2阳性临床样本和相应的COVID-19 Genomics UK Consortium（COG-UK）测序数据评估另外两个关注的突变。我们证明，基因分型是一种强大的深入技术，用于识别特定的突变，是一个很好的补充，基因组测序，并具有真实的临床健康价值的潜力，使实验室能够更快地报告和采取行动的变异关注。
Genome sequencing is a powerful tool for identifying SARS-CoV-2 variant lineages; however, there can be limitations due to sequence dropout when used to identify specific key mutations. Recently, ThermoFisher Scientific has developed genotyping assays to help bridge the gap between testing capacity and sequencing capability to generate real-time genotyping results based on specific variants. Over a 6-week period during the months of April and May 2021, we set out to assess the ThermoFisher TaqMan mutation panel genotyping assay, initially for three mutations of concern and then for an additional two mutations of concern, against SARS-CoV-2-positive clinical samples and the corresponding COVID-19 Genomics UK Consortium (COG-UK) sequencing data. We demonstrate that genotyping is a powerful in-depth technique for identifying specific mutations, is an excellent complement to genome sequencing, and has real clinical health value potential, allowing laboratories to report and take action on variants of concern much more quickly.